Download pdf
Application of CRISPR/Cas9 on multiple sclerosis target validation
- 1 Monash University
* Author to whom correspondence should be addressed.
Abstract
Multiple Sclerosis is one of the serious diseases worldwide. Demyelination of neurons in the central nervous system is its fundamental cause. Genome engineering for various MS research has recently undergone a revolution since the establishment of the clustered regularly interspaced short palindromic repeats (CRISPR) technology. This includes research spanning from basic science to translational medicine and precise MS therapy. Researchers have been able to identify, visualise, modify, and annotate specific DNA and RNA regions in a variety of living organisms thanks to the prokaryote-derived genome editing systems CRISPR/CRISPR associated proteins (CRISPR/Cas).The identification, validation, and targeted delivery of the target are all significantly aided by the CRISPR/Cas systems. With considerable technical developments, CRISPR/Cas systems have proved to be very effective, accurate, and flexible when targeting the specified genetic site. Despite major advancements in this area, a number of challenges still need to be solved, including immunological reactions, off-target activities, and ethical concerns. The following article aims to provide an overview of the CRISPR clinical applications, including their benefits and drawbacks.
Keywords
CRISPR/Cas 9, multiple sclerosis, target validation, off-target, ethical principles
[1]. Zhang, H., Qin, C., An, C., Zheng, X., Wen, S., Chen, W., Liu, X., Lv, Z., Yang, P., Xu, W., Gao, W., & Wu, Y. (2021). Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. Molecular Cancer, 20, 126. https://doi.org/10.1186/s12943-021-01431-6
[2]. Dobson, R., & Giovannoni, G. (2018). Multiple sclerosis - a review. European Journal of Neurology, 26(1), 27–40. https://doi.org/10.1111/ene.13819
[3]. Wilson, H. C., Onischke, C., & Raine, C. S. (2003). Human oligodendrocyte precursor cells in vitro: Phenotypic analysis and differential response to growth factors. Glia, 44(2), 153–165. https://doi.org/10.1002/glia.10280
[4]. Wekerle, H. (2008). Lessons from multiple sclerosis: models, concepts, observations. Annals of the Rheumatic Diseases, 67(3), iii56–iii60. https://doi.org/10.1136/ard.2008.098020
[5]. Petzold, A., & Shaw, G. (2007). Comparison of two ELISA methods for measuring levels of the phosphorylated neurofilament heavy chain. Journal of Immunological Methods, 319(1-2), 34–40. https://doi.org/10.1016/j.jim.2006.09.021
[6]. Irizar, H., Muñoz-Culla, M., Sáenz-Cuesta, M., Osorio-Querejeta, I., Sepúlveda, L., Castillo-Triviño, T., Prada, A., Lopez de Munain, A., Olascoaga, J., & Otaegui, D. (2015). Identification of ncRNAs as potential therapeutic targets in multiple sclerosis through differential ncRNA – mRNA network analysis. BMC Genomics, 16(1), 250. https://doi.org/10.1186/s12864-015-1396-5
[7]. Zahoor, I., Rui, B., Khan, J., Datta, I., & Giri, S. (2021). An emerging potential of metabolomics in multiple sclerosis: a comprehensive overview. Cellular and Molecular Life Sciences, 78(7), 3181–3203. https://doi.org/10.1007/s00018-020-03733-2
[8]. Lee, M. H., Shin, J. I., Yang, J. W., Lee, K. H., Cha, D. H., Hong, J. B., Park, Y., Choi, E., Tizaoui, K., Koyanagi, A., Jacob, L., Park, S., Kim, J. H., & Smith, L. (2022). Genome Editing Using CRISPR-Cas9 and Autoimmune Diseases: A Comprehensive Review. International Journal of Molecular Sciences, 23(3), 1337. https://doi.org/10.3390/ijms23031337
[9]. Petersen, M. A., Ryu, J. K., Chang, K.-J., Etxeberria, A., Bardehle, S., Mendiola, A. S., Kamau-Devers, W., Fancy, S. P. J., Thor, A., Bushong, E. A., Baeza-Raja, B., Syme, C. A., Wu, M. D., Rios Coronado, P. E., Meyer-Franke, A., Yahn, S., Pous, L., Lee, J. K., Schachtrup, C., Lassmann, H., Huang, E. J., Han, M. H., Absinta, M., Reich, D. S., Ellisman, M. H., Rowitch, D. H., Chan, J. R., & Akassoglou, K. (2017). Fibrinogen Activates BMP Signaling in Oligodendrocyte Progenitor Cells and Inhibits Remyelination after Vascular Damage. Neuron, 96(5), 1003-1012.e7. https://doi.org/10.1016/j.neuron.2017.10.008
[10]. Johansen, K. H. (2021). How CRISPR/Cas9 Gene Editing Is Revolutionizing T Cell Research. DNA and Cell Biology, 41(1), 53–57. https://doi.org/10.1089/dna.2021.0579
[11]. Kirk, R. G. W. (2017). Recovering The Principles of Humane Experimental Technique. Science, Technology, & Human Values, 43(4), 622–648. https://doi.org/10.1177/0162243917726579
[12]. Ustiugova, A. S., Dvorianinova, E. M., Melnikova, N. V., Dmitriev, A. A., Kuprash, D. V., & Afanasyeva, M. A. (2023). CRISPR/Cas9 genome editing demonstrates functionality of the autoimmunity-associated SNP rs12946510. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1869(4), 166599. https://doi.org/10.1016/j.bbadis.2022.166599
[13]. Yang, Y., Xu, J., Ge, S., & Lai, L. (2021). CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research. Frontiers in Medicine, 8, 649896. https://doi.org/10.3389/fmed.2021.649896
[14]. RodriguezRodriguez, D., RamirezSolis, R., GarzaElizondo, M., GarzaRodriguez, M., & BarreraSaldaia, H. (2019). Genome editing: A perspective on the application of CRISPR/Cas9 to study human diseases (Review). International Journal of Molecular Medicine, 43(4), 1559–1574. https://doi.org/10.3892/ijmm.2019.4112
[15]. Caplan, A. L., Parent, B., Shen, M., & Plunkett, C. (2015). No time to waste--the ethical challenges created by CRISPR. EMBO Reports, 16(11), 1421–1426. https://doi.org/10.15252/embr.201541337
[16]. Madill, M., Fitzgerald, D., O’Connell, K. E., Dev, K. K., Shen, S., & FitzGerald, U. (2016). In vitro and ex vivo models of multiple sclerosis. Drug Discovery Today, 21(9), 1504–1511. https://doi.org/10.1016/j.drudis.2016.05.018
[17]. Ikeda, K., Uchida, N., Nishimura, T., White, J., Martin, R. M., Nakauchi, H., Sebastiano, V., Weinberg, K. I., & Porteus, M. H. (2018). Efficient scarless genome editing in human pluripotent stem cells. Nature Methods, 15(12), 1045–1047. https://doi.org/10.1038/s41592-018-0212-y
[18]. Elliott, E. K., Haupt, L. M., & Griffiths, L. R. (2021). Mini review: genome and transcriptome editing using CRISPR-cas systems for haematological malignancy gene therapy. Transgenic Research, 30(2), 129–141. https://doi.org/10.1007/s11248-020-00232-9
Cite this article
Qin,D. (2024). Application of CRISPR/Cas9 on multiple sclerosis target validation. Theoretical and Natural Science,72,21-26.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 4th International Conference on Biological Engineering and Medical Science
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).